Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma Witzig, T. E., Sokol, L., Kim, W., de la Cruz Vicente, F., Caballero, D., Advani, R., de Ona, R., Marin Niebla, A., Jose Terol, M., Domenech Eva, D., Bendris, N., Mackey Ahsan, J., Leoni, M., Foss, F. M. AMER SOC HEMATOLOGY. 2021

View details for DOI 10.1182/blood-2021-147279

View details for Web of Science ID 000736398802161